lilly tirzepatide self pay Eli is now offering four doses of Zepbound in self-administration vials. The lower-cost self-pay option targets people on Medicare and those who can no longer access compounded tirzepatide. Click the link Eli Lilly adds high-dose Zepbound

Synovial sarcoma mimicking benign peripheral nerve sheath tumor

Knowing where to seek care can be confusing when vision problems arise

Injecting into the same site repeatedly is among the most common mistakes, leading to tissue damage, discomfort, and increased injection-site reactions

[1] Clinical trials have demonstrated substantial reductions in hemoglobin A1c (HbA1c) levelsoften exceeding 2% from baselinealong with clinically meaningful weight loss that varies by dose and indication (approximately 15-20% of body weight in obesity trials at the highest doses, with lower percentages typically seen in diabetes trials)